CS Paper Radar

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

Jiacheng Lin, Zifeng Wang, Zheng Chen, Erick Scott, Ziwei Yang, Fanyang Yu, Sheng Zhong, Jimeng Sun

cs.CL ·submitted 2026-09-18 14:53 UTC · v1

Abstract

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.

Closest papers

Nearest neighbours by meaning across the whole index.

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

cs.AI cs.CLstat.AP ·2026-11-09 ·Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen +3 more
publishedbenchmarkcode/data similarity 0.74
Abstract · 13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and da…

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

0.45

VITAL: A Framework for Validating Agentic AI in Pharmaceutical Drug Development and Clinical Trial Operations

cs.AI ·2026-11-17 ·Sandeep Burugupalli, Pedro Matos-Filipe, Andrea Hita Ardiaca, Adam Taylor, Alex Grigorenko +8 more
similarity 0.69
Abstract

Current assurance approaches do not establish whether evidence is sufficient to validate, monitor and govern agentic artificial intelligence (AI) within a pharmaceutical context of use. Plausible outputs may conceal failures in retrieval, reasoning, orchestration or human-control points, where reference standards are unavailable. We developed and operationalised VITAL (Validation by Intended use, Traceability, Autonomy and Lifecycle evidence), a validation framework for agents in clinical development, through landscape analysis, regulatory and standards mapping, expert interviews and multi-stakeholder refinement. VITAL integrates context of use, controls, behavioural validation and lifecycle evidence within a risk-adjusted framework. We applied VITAL across epidemiology and treatment-landscape analysis, site selection, enrolment rescue and trial-design trade-off support to translate autonomy, reversibility, transparency and patient impact into proportionate validation activities, evidence requirements and auditable reconstruction of system behaviour. VITAL may inform evidence requirements and lifecycle accountability for higher-risk pharmaceutical uses; evaluation should assess reproducibility across assessors, organisations and system configurations.

0.25

DrugHarness: An Evolvable Agent Harness for Computational Drug Discovery

cs.AI ·2026-10-16 ·Yuxing Chen, Zhisheng Zhang, Cheng Tang, Wei Li, Minghui Zhang +18 more
hot direction similarity 0.68
Abstract

Computational drug discovery requires agents to compose scientific operations and adapt to changing evidence and constraints. Here we introduce DrugHarness, an evolvable agent harness coupling composable scientific execution with conditional skill induction. Its environment integrates over 80 scientific operations, biomedical resources and task-specific code, preserving associations among candidates, results and artifacts. From execution trajectories and outcome feedback, DrugHarness induces action hypotheses with observable applicability conditions, recommended actions and supporting evidence. An independent review agent evaluates candidate skills derived from these hypotheses through source verification and, when needed, targeted execution trials. Admitted skills guide subsequent tasks and are revised through feedback. Evaluation on MolBench and SMDD-Bench demonstrates capabilities in molecular screening, optimization and constrained design. Without evolution, DrugHarness exceeds reported MolClaw-CC results by 10.8 percentage points in affinity-comparison accuracy and 55% in mean top-three active hits on MolBench. Retrospective evaluation on skill-development tasks shows that evolution increases Qwen's affinity-comparison accuracy from 62.2% to 81.1% and optimization success from 79.5% to 87.2%. In a prospective HPK1 study, DrugHarness achieves a more favorable median docking score than Biomni among system-specific candidates. A synthesized compound achieves a cellular IC50 of 14.19 nM, a 2.64-fold potency improvement over the best input reference, with activity competitive with two selected compounds designed by experienced medicinal chemists. These results support conditional skill evolution for scientific agents and demonstrate a workflow connecting computational drug design with experimental validation.

0.25

Disease-level drug approval forecasting from trial-agnostic public data

cs.LG q-bio.QM ·2026-09-29 ·Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos
similarity 0.66
Abstract

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through early program advancement and disease prioritization. Yet existing approaches predict outcomes at a single level or stage or do not distinguish between disease outcomes for the same drug. We ask (1) whether FDA approval can be forecast for a drug-disease pair using only pre-clinical trial information, and (2) whether these forecasts can help prioritize diseases for the same drug. We built a cohort of 14,134 drug-disease pairs by reconstructing programs from ClinicalTrials.gov, extracting disease-level approvals from FDA label documentation, and enriching each pair with molecular, disease, ADMET, target, and pathway features. We divided the cohort into pre- and post-2019 programs and trained a classifier on pre-2019 data to predict FDA approval. On the post-2019 cohort (2,637 programs), the model would have prioritized a program that ultimately gained approval over one that did not approximately three out of four times. For drugs tested across multiple diseases, selecting the model's highest-ranked disease would have identified an ultimately approved disease 61.3% of the time, compared with 40.7% under random selection. These results show that public pre-trial information contains signal for forecasting FDA approval at the drug-disease level and can help prioritize diseases for the same drug. We provide a public web tool for SMILES- and ICD-10-based drug-disease approval forecasting.

0.14

VirtualTrialHarness: Coordinating Agentic Operationalization of Virtual Trial Protocols Across Complex Clinical Schemas

cs.AI ·2026-11-03 ·Pengze Li, Jingna Feng, Yue Yu, Yining Wu, Xinyue Hu +3 more
similarity 0.64
Abstract

Virtual trials use routinely collected clinical data to evaluate treatment strategies, but translating a study protocol into an executable analysis requires determining how clinical concepts and study requirements should be represented in the available data and applied consistently across the workflow. These decisions depend on local data representations and operational conventions and can involve source selection, patient and encounter identity, linkage, and temporal interpretation. Here we introduce VirtualTrialHarness (VTHarness), an agent framework that coordinates virtual-trial operationalization by selecting reusable procedural skills for each workflow stage and uses explicit contracts to maintain consistent study decisions across stages. We also introduce VTBenchmark for evaluating source selection and cohort construction. Across three complex synthetic environments, VTHarness successfully produced all required cohort outputs matching the references in 95.1% of workflows after requirement clarification, compared with 60.4% using retrieval from the same procedural corpus. Procedural skills improved source recovery across three language models and increased source overlap with analyst code in 13 Mayo Clinic cases. Site-specific adaptation enabled reference-matched cohort execution across eight MIMIC-IV tasks. Within the Mayo Clinic Virtual Trials Program, the framework supported investigator review of cohort construction and endpoint analysis. These findings support coordinating procedural guidance with workflow decisions to improve virtual-trial implementation across complex clinical schemas.

0.10

M3OS: A Monte Carlo Graph Search-Orchestrated Multi-Agent LLM System for Evidence-Traced Molecular Optimization

cs.LG q-bio.BM ·2026-09-28 ·Junjie Wang, Yaowei Jin, Ruohui Tang, Guonan Cui, Haojie Wang +5 more
similarity 0.64
Abstract

Small-molecule optimization integrates medicinal-chemistry reasoning and computational evidence through iterative, multi-objective decisions. When large language models (LLMs) reason over optimization histories stored primarily in conversational context, they must recover candidate identities, prior evaluations, and task constraints to guide subsequent decisions. We present M3OS, a multi-agent LLM system that decouples molecular-design reasoning from optimization-state management through Monte Carlo graph search. A persistent graph links evaluated candidates, parent-child transformations and evaluation evidence, while rewards and visit statistics guide LLM-assisted parent selection. Two branches combine tool-driven candidate generation with knowledge- and case-guided medicinal-chemistry editing. An execution harness controls graph updates through structured output extraction, molecular validation and task-bound evaluation. Agents receive role-specific contexts, while the graph preserves optimization trajectories beyond their active contexts. Across three molecular optimization benchmarks, M3OS achieves higher success rates than baselines, supporting the integration of persistent search state, specialized agents and controlled execution for multi-constraint optimization.

0.21

ClinAgent: A ReAct-Based Agent for Conversational Access to Clinical Trial Information

cs.AI cs.CLcs.IR ·2026-09-12 ·Antonino Vaccarella, Riccardo Cantini, Domenico Talia, Paolo Trunfio, Marianna Talia +2 more
published similarity 0.64
Abstract · Accepted at the CIBB 2026 conference (https://cibb2026.teralab.ai/)

Querying clinical trial registries remains a manual and error-prone process, requiring researchers to navigate large volumes of semi-structured data without support for natural language interaction or cross-source synthesis. To address this, we introduce ClinAgent, a conversational system based on agentic Retrieval-Augmented Generation (RAG) that enables clinicians and researchers to query clinical trial information in plain language and receive grounded, up-to-date responses across multi-turn interactions. The system centers on a Large Language Model (LLM) agent following the ReAct paradigm, which iteratively reasons over queries, selects among a set of integrated tools, and refines its actions based on intermediate outputs. These tools include a ClinicalTrials.gov search interface, a PubMed module, and a Python-based analyzer operating on a locally cached structured dataset of clinical trials. We evaluate the system using a three-phase framework assessing operational effectiveness, planning quality, tool-use efficiency, and expert qualitative judgments, comparing three LLM backends: Gemini 3.0 Flash and two variants of DeepSeek V3.2 (thinking and non-thinking). Results reveal complementary strengths, with DeepSeek (thinking mode) excelling in planning quality, while Gemini achieves the highest overall performance and strongest expert ratings. Overall, our findings highlight the potential of agentic AI systems to improve the accessibility and synthesis of clinical trial information, supporting more efficient and user-centered biomedical research workflows.

0.29

Designing a Robust LLM-Based Evaluation System for Agentic AI in Drug Discovery Through Human Alignment

cs.LG ·2026-08-21 ·Emma Granqvist, Rocío Mercado, Samuel Genheden
similarity 0.62
Abstract

Agentic large language model (LLM) systems are reshaping scientific workflows in chemistry and drug discovery, but evaluating their open-ended, tool-augmented outputs remains a fundamental bottleneck. The LLM-as-a-Judge paradigm has emerged as a scalable alternative, but existing drug discovery benchmarks deploy LLM judges without validating their alignment with human experts. In this work, we present an LLM-as-a-Judge evaluation framework for ChatInvent, an agentic drug discovery assistant deployed at AstraZeneca, with five contributions. First, we define four output-quality evaluation dimensions---Completeness, Relevancy, Structural Clarity, and Scope Adherence---alongside deterministic Tool Call Correctness checks. Second, we validate the judge through a human alignment study with five expert annotators, comparing Gemini 3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B as candidate judges. Third, we optimize the best-performing judge using few-shot demonstrations of human-annotated examples, improving alignment with the human majority vote from 0.80 to 0.86. Fourth, applying the optimized judge to 70 held-out questions, we surface concrete limitations and find no strong evidence that informal phrasing degrades output quality; it may, however, still be helpful to have the LLM rewrite the original question before querying the agent. Finally, we extend the framework to 38 adversarial questions that are ambiguous, invalid, out-of-scope or ethically sensitive, and show that the agent's refusal behavior is guided by the stated intent of a request. Our framework provides a reusable template for human-aligned evaluation of agentic systems in scientific domains.

0.24